[1] |
HOU Qiong, LIU Fei, CHEN Chuanrong.
Immunotherapy combined with anti-angiogenic drugs and chemotherapy in negative driver gene and advanced non-small cell lung cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 775-779.
|
[2] |
DANG Zilong, LIU Haiyang, ZHANG Yangfan, LIU Jinfeng, ZHANG Tianwei, LI Bin, GUO Hong, CHENG Wenyuan, XU Xiaohui, LI Yile, WEI Yuhui, WU Xin'an.
Optimization strategy of antibiotic dosing regimen in intensive care unit patients with augmented renal clearance
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 561-571.
|
[3] |
ZHANG Mingkang, MA Yanrong, JIN Yongwen, ZHOU Yan, CUI Ruirui, WU Xin'an.
Advances in clinical research on drug-induced acute interstitial nephritis
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 419-428.
|
[4] |
LI Ruoning, GUO Zhanli, WANG Yuan, SUN Jianjun.
Platelet-endothelial aggregation receptor 1 and its mediated signalling pathway Advances in the study of the role of platelets and endothelial cells
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 438-444.
|
[5] |
DAI Jiahui, SUN Sijia, XIE Xuefeng.
Quality management and indicator system for clinical trials of medical devices
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 51-58.
|
[6] |
CAI Jing, PAN Binjing, LIU Jingfang.
Research progress on the relationship between hypoglycemic drugs and sarcopenia
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 101-108.
|
[7] |
MIAO Yadong, LI Xi, WANG Yan, GAO Po, ZHOU Min, YU Hao.
General considerations for clinical data management of antineoplastic drugs
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 1055-1060.
|
[8] |
YAN Yukui, HU Jianqin, ZHANG Bing.
Clinical study of new and conventional antiepileptic drugs with newly diagnosed partial epilepsy
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 793-799.
|
[9] |
ZHU Lili, ZHU Xiuxiu, WANG Wenjun, ZHANG Hailin, LIN Li.
Clinical trials of inhalation in pediatric population in China
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(2): 178-183.
|
[10] |
DUAN Ruixiao, ZHAO Yifan, YE Yongjuan, LIU Min, LI Qiang, ZHOU Yongning.
Mechanism of action of bile acid metabolism in regulating inflammatory bowel disease and the research and development of drugs
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(10): 1171-1181.
|
[11] |
XU Hui, YANG Xinyu, ZHAO Zhehui, WANG Yan.
Research progress and thinking on the metabolism of polysaccharide drugs in vivo and the key technology of PK/PD
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(8): 851-862.
|
[12] |
LIU Lu, CHEN Xiaoyan.
Current status of clinical drug-drug interactions research of innovative small molecule drugs in China
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(8): 863-875.
|
[13] |
WANG Yuanyuan, HONG Yu, ZHANG Lei, YIN Fangxiong, LEI Ting, ZHU Xi.
Establishment and application of DUE criteria for human albumin in pediatric patients
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(6): 653-661.
|
[14] |
LIU Xing, WU Ying, LI Yang, WANG Xiaomin.
Analysis of ethical issue in the application of artificial intelligence medical devices
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(6): 695-699.
|
[15] |
SHI Yingzi, ZHAO Yang.
Impact of China-US drug regulatory incentives on local innovative drug simultaneous development in multiple countries: An empirical study based on zanubrutinib
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(5): 560-569.
|